Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines

Authors not listed

The Jackson Laboratory · 2017

Abstract

This is a prospective, single-site, randomized, then open-label study designed to develop a detailed transcriptional and epigenetic profile of the immune response to pneumococcal vaccination with conjugated and non-conjugated polysaccharide vaccines in the senescent immune system of older adults. In this study, 40 healthy adults ages 60 and older that have never received pneumococcal vaccination, will be randomized in a 1:1 ratio to receive Prevnar-13 (Pfizer), a conjugated 13-valent vaccine or Pneumovax 23 (Merck), a non-conjugated 23-valent vaccine. Following randomized assignment of vaccine, the study will be open-label. Six (6) study visits will occur over about 70 days, with an optional 7th visit for participants to receive a second vaccination with the other pneumococcal vaccine one to two years after randomization. Participants will provide blood samples for transcriptional, epigenetic and biological analyses pre- and post-vaccination.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-24 MST

Cite this

APA
Anonymous. (2017). Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines. <em>The Jackson Laboratory</em>. https://clinicaltrials.gov/study/NCT03104075
Vancouver
Anonymous. Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines. The Jackson Laboratory. 2017.
BibTeX
@misc{anon2017Genomi, title = {Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines}, author = {Anonymous}, journal = {The Jackson Laboratory}, year = {2017}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings